WEST PHARMACEUTICAL SERVICES INC Initial Statement of Beneficial Ownership

West Pharmaceutical Services reported insider equity holdings for a senior executive.

Rhea-AI Filing Summary

West Pharmaceutical Services reported insider equity holdings for a senior executive. The reporting person is an officer of the company, serving as SVP, General Counsel and Corporate Secretary. The filing shows derivative holdings including 192 restricted stock units tied to West Pharmaceutical common stock, which vest in four equal installments beginning on December 8, 2026. It also discloses a stock option covering 459 shares of common stock with an exercise price of $269.08 per share and an expiration date of December 8, 2035. These details outline part of the executive’s long-term, equity-based compensation linked to the company’s share performance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Finch Norman D. Jr.

Role SVP, GC & Corporate Secretary

Type	Security	Shares	Price	Value
holding	Rst. Stock Unit	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Rst. Stock Unit — 192 contracts (Direct); Stock Option (Right to Buy) — 459 contracts (Direct)

Footnotes (1)

1. F1. This award vests in four equal installments beginning on December 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/10/2025 - 10:32 AM EST Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Finch Norman D. Jr.

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/09/2025

3. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GC & Corporate Secretary

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	(1)	Common Stock	192	$0	D
Stock Option (Right to Buy)	12/08/2026(1)	12/08/2035	Common Stock	459	$269.08	D

Explanation of Responses:

1. This award vests in four equal installments beginning on December 8, 2026.

	/s/ Louis Lalli, as an agent for Norman D. Finch, Jr.	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.